Strauss joins as chief clinical and commercial officer, while Kaswan takes over the chief financial officer role. Both hires bring decades of experience to the brain-computer interface (BCI) technology developer.
Precision Neuroscience develops the Layer 7 Cortical Interface, which features 1,024 tiny electrodes spanning an area of one square centimeter. The company embedded the electrodes in a flexible film that conforms to the brain surface.
The film comes in at one-fifth the thickness of a human hair. Precision Neuroscience designed it for implantation and removal by neurosurgeons without damaging brain tissue. The company wants to use its brain-computer interface to map a large area of the brain’s surface at resolutions higher than typical neurosurgical procedures.
Precision Neuroscience is featured on MassDevice’s 2023 list of BCI companies you need to know. The company plans to release its first commercial product next year.
More about the new Precision Neuroscience additions
Strauss will lead the company’s efforts to establish research partnerships with hospitals and health systems throughout the U.S. Additionally, she will aim to drive adoption of the company’s first commercial product.
Prior to joining Precision Neuroscience, Strauss served as chief clinical officer at Viz.ai. She also trained as a neuro ICU nurse and spent a decade as a hospital executive.
Kaswan brings more than 30 years of financial leadership experience, including time spent in C-suite roles at high-growth companies. Most recently, he held the post of CFO at Orchestra BioMed, which he helped take public last year. He also co-founded three businesses in the past and spent time as a healthcare-focused venture capital investor for more than 10 years.
“As Precision moves closer to commercialization, we’re focussing on recruiting exceptional talent with the vision and skill to support the next chapter of the company’s growth,” said Michael Mager, CEO of Precision Neuroscience. “Both Jayme and Mike bring invaluable experience to our team as we work to bring this technology to the clinic in coming years.”
